The United Kingdom has approved trials by London-based Small Pharma for assessing the safety, and later efficacy, of N,N-dimethyltryptamine – or DMT – for depression, according to a Pharm Exec report. It is the world’s first clinical trial for studying DMT as a depression treatment.
MindMed announces a successful pre-Investigational New Drug meeting with the FDA regarding its Project Lucy (LSD) research for anxiety.
Eleusis acquires a ketamine therapy provider and announces a new R&D program.
MindMed continues to raise capital. This time issuing 11,364,000 units at CAD$4.40 for gross proceeds of CAD$50,001,600.
They’ve been credited in part for the musical and artistic revolutions of the late 1960s. According to some scientific opinions, they have potentially inspired early creativity in humans and our ancient ancestors.
Psychedelic stocks are hitting new highs -- and doing so on record trading volumes. Feeding frenzies.
One month after Arizona voters overwhelmingly approved a ballot initiative to legalize marijuana for adult use, regulators have already put forward draft regulations to implement the program.
MindMed's recent financing has closed after being upsized all the way to CAD$34.5 million.
The company is set to open a therapeutic health and training center in Kelowna, British Columbia in May of 2021
Leading psychedelic stocks have gone ballistic in recent weeks. But where will investors find the NEXT multi-bagger opportunity?
Entheon has secured a supply of DMT for delivery to its drug research center (CHDR) in the Netherlands.
Champignon Brands names an interim CFO after Stephen Brohman resigns.
Canada will allow a handful of health care professionals to possess and consume psilocybin mushrooms in order to better treat the growing number of patients now permitted to use the psychedelic drug, the country’s top health official revealed in a recent interview.
Mind Cure's initial R&D focus will be on psilocybin, ketamine and ibogaine. Researching both pain and mental health applications for psychedelics.
Seven in ten Americans support clearing the records of people with non-violent marijuana convictions, according to a new poll.
